Clinical trial · no report yet · Phase 3
PERSEE
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
- NCT04547504 ↗
- Active, not recruiting
- University Hospital, Brest
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small-cell Lung Cancer
- Interventions
- Pembrolizumab; Pembrolizumab and Chemotherapy drugs
- Arms
- Pembrolizumab · Active comparator
- Chemotherapy-Pembrolizumab · Active comparator
- Enrollment
- 349
- Primary outcomes
- Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR)
- Sponsor
- University Hospital, Brest with Groupe Francais De Pneumo-Cancerologie
- Start
- Dec 22, 2020
- Primary completion
- Dec 22, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT04547504 · updated Sep 17, 2025
Publications
linked from the registry- Descourt R, Chouaid C, Perol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac JB, Robinet G, Decroisette C. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression >/=50. Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22. PubMed 34156285